These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 27401521)

  • 1. Defining secondary progressive multiple sclerosis.
    Lorscheider J; Buzzard K; Jokubaitis V; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Alroughani R; Sola P; Boz C; Pucci E; Lechner-Scott J; Bergamaschi R; Oreja-Guevara C; Iuliano G; Van Pesch V; Granella F; Ramo-Tello C; Spitaleri D; Petersen T; Slee M; Verheul F; Ampapa R; Amato MP; McCombe P; Vucic S; Sánchez Menoyo JL; Cristiano E; Barnett MH; Hodgkinson S; Olascoaga J; Saladino ML; Gray O; Shaw C; Moore F; Butzkueven H; Kalincik T;
    Brain; 2016 Sep; 139(Pt 9):2395-405. PubMed ID: 27401521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining reliable disability outcomes in multiple sclerosis.
    Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
    Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
    Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
    Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses and disability accumulation in progressive multiple sclerosis.
    Paz Soldán MM; Novotna M; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Jan; 84(1):81-8. PubMed ID: 25398229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.
    Kremenchutzky M; Cottrell D; Rice G; Hader W; Baskerville J; Koopman W; Ebers GC
    Brain; 1999 Oct; 122 ( Pt 10)():1941-50. PubMed ID: 10506095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
    Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early clinical markers of aggressive multiple sclerosis.
    Malpas CB; Manouchehrinia A; Sharmin S; Roos I; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Eichau S; Bergamaschi R; Sola P; Ferraro D; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Grand'Maison F; Ozakbas S; Van Pesch V; Granella F; Hupperts R; Pucci E; Boz C; Sidhom Y; Gouider R; Spitaleri D; Soysal A; Petersen T; Verheul F; Karabudak R; Turkoglu R; Ramo-Tello C; Terzi M; Cristiano E; Slee M; McCombe P; Macdonell R; Fragoso Y; Olascoaga J; Altintas A; Olsson T; Butzkueven H; Hillert J; Kalincik T
    Brain; 2020 May; 143(5):1400-1413. PubMed ID: 32386427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
    Kalincik T; Vivek V; Jokubaitis V; Lechner-Scott J; Trojano M; Izquierdo G; Lugaresi A; Grand'maison F; Hupperts R; Oreja-Guevara C; Bergamaschi R; Iuliano G; Alroughani R; Van Pesch V; Amato MP; Slee M; Verheul F; Fernandez-Bolanos R; Fiol M; Spitaleri DL; Cristiano E; Gray O; Cabrera-Gomez JA; Shaygannejad V; Herbert J; Vucic S; Needham M; Petkovska-Boskova T; Sirbu CA; Duquette P; Girard M; Grammond P; Boz C; Giuliani G; Rio ME; Barnett M; Flechter S; Moore F; Singhal B; Bacile EA; Saladino ML; Shaw C; Skromne E; Poehlau D; Vella N; Spelman T; Liew D; Kilpatrick TJ; Butzkueven H;
    Brain; 2013 Dec; 136(Pt 12):3609-17. PubMed ID: 24142147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T;
    Neurology; 2017 Sep; 89(10):1050-1059. PubMed ID: 28794248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.